Hematopoietic Cell Transplantation for Aplastic Anemia

George E. Georges*, Rainer Storb

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Scopus citations

Abstract

Aplastic anemia (AA) is a rare disease characterized by pancytopenia and marrow parenchyma that is lacking hematopoietic elements. This chapter summarizes the results of marrow hematopoietic cell transplantation (HCT) for severe AA over the past 40 years. Early reports of marrow HCT for SAA identified three major transplant-related problems: graft rejection; acute graft-versus-host disease (GVHD); and chronic GVHD. The largest number of transplants for SAA performed to date have been from human leukocyte antigen (HLA)-matched sibling donors. There are at least two reasons for the improved survival of patients with AA who were treated with HLA-identical HCT. One is the decreased incidence of graft rejection. The second reason for improved survival has been a decrease in the incidence and severity of acute GVHD through the introduction of better GVHD prevention regimens, such as combined MTX-CSP.

Original languageEnglish (US)
Title of host publicationThomas' Hematopoietic Cell Transplantation
Subtitle of host publicationFifth Edition
PublisherWiley-Blackwell
Pages517-540
Number of pages24
Volume1-2
ISBN (Electronic)9781118416426
ISBN (Print)9781118416006
DOIs
StatePublished - Jan 1 2016

Keywords

  • Aplastic anemia
  • Bone marrow transplantation
  • Graft rejection
  • Graft-versus-host disease
  • Hematopoietic cell transplantation
  • Human leukocyte antigen

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Hematopoietic Cell Transplantation for Aplastic Anemia'. Together they form a unique fingerprint.

Cite this